Recombinant Anti-PAR4 antibody [EPR3991] (ab92590)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR3991] to PAR4
- Suitable for: WB, IP
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-PAR4 antibody [EPR3991]
See all PAR4 primary antibodies -
Description
Rabbit monoclonal [EPR3991] to PAR4 -
Host species
Rabbit -
Tested applications
Suitable for: WB, IPmore details
Unsuitable for: Flow Cyt,ICC/IF or IHC-P -
Species reactivity
Reacts with: Human
Predicted to work with: Mouse -
Immunogen
Synthetic peptide within Human PAR4 aa 1-100 (N terminal). The exact sequence is proprietary.
-
Positive control
- LNCap, Jurkat, A549 and HeLa cell lysates
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Rat: We have preliminary internal testing data to indicate this antibody may not react with this species. Please contact us for more information.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C. -
Storage buffer
pH: 7.20
Preservative: 0.05% Sodium azide
Constituents: 0.1% BSA, 40% Glycerol (glycerin, glycerine), 9.85% Tris glycine, 50% Tissue culture supernatant -
Concentration information loading...
-
Purity
Tissue culture supernatant -
Clonality
Monoclonal -
Clone number
EPR3991 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Positive Controls
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab92590 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/10000 - 1/50000. Predicted molecular weight: 37 kDa.
|
|
IP |
1/10 - 1/100.
|
Notes |
---|
WB
1/10000 - 1/50000. Predicted molecular weight: 37 kDa. |
IP
1/10 - 1/100. |
Target
-
Function
Pro-apoptopic protein capable of selectively inducing apoptosis in cancer cells, sensitizing the cells to diverse apoptotic stimuli and causing regression of tumors in animal models. Induces apoptosis in certain cancer cells by activation of the Fas prodeath pathway and coparallel inhibition of NF-kappa-B transcriptional activity. Inhibits the transcriptional activation and augments the transcriptional repression mediated by WT1. Down-regulates the anti-apoptotic protein BCL2 via its interaction with WT1. Seems also to be a transcriptional repressor by itself. May be directly involved in regulating the amyloid precursor protein (APP) cleavage activity of BACE1. -
Tissue specificity
Widely expressed. Expression is elevated in various neurodegenerative diseases such as amyotrophic lateral sclerosis, Alzheimer, Parkinson and Huntington diseases and stroke. Down-regulated in several cancers. -
Domain
The leucine-zipper domain is not essential for apoptosis, but is required for sensitization of cells to exogenous apoptotic insults and for interaction with its partners.
The SAC domain is a death-inducing domain selective for apoptosis induction in cancer cells. This domain is essential for nuclear entry, Fas activation, inhibition of NF-kappa-B activity and induction of apoptosis in cancer cells. -
Post-translational
modificationsPreferentially phosphorylated at the Thr-163 by PKC in cancer cells. -
Cellular localization
Cytoplasm. Nucleus. Mainly cytoplasmic in absence of apoptosis signal and in normal cells. Nuclear in most cancer cell lines. Nuclear entry seems to be essential but not sufficient for apoptosis (By similarity). Nuclear localization includes nucleoplasm and PML nuclear bodies. - Information by UniProt
-
Database links
- Entrez Gene: 5074 Human
- Entrez Gene: 114774 Mouse
- Omim: 601936 Human
- SwissProt: Q96IZ0 Human
- SwissProt: Q925B0 Mouse
- Unigene: 643130 Human
- Unigene: 391419 Mouse
-
Alternative names
- 2310001G03Rik antibody
- PAR 4 antibody
- PAR-4 antibody
see all
Images
-
All lanes : Anti-PAR4 antibody [EPR3991] (ab92590) at 1/10000 dilution
Lane 1 : LNCap cell lysate
Lane 2 : Jurkat cell lysate
Lane 3 : A549 cell lysate
Lane 4 : HeLa cell lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 37 kDa -
ab92590 at 1/40 immunoprecipitating PAR4 in Jurkat (human T cell leukemia T lymphocyte) whole cell lysate.
Lane 1 (+): ab92590 + Jurkat whole cell lysate
Lane 2 (-): PBS instead of ab92590 in Jurkat whole cell lysate
For western blotting, ab92590 was at 1/1000 dilution followed by Goat Anti-Rabbit IgG, (HRP), specific to the non-reduced form of IgG as the secondary antibody (1/1500).
Blocking buffer and concentration: 5% NFDM/TBST.
Diluting buffer and concentration: 5% NFDM /TBST.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (2)
ab92590 has been referenced in 2 publications.
- Zhang Y et al. CircTRRAP Knockdown Has Cardioprotective Function in Cardiomyocytes via the Signal Regulation of miR-370-3p/PAWR Axis. Cardiovasc Ther 2022:7125602 (2022). PubMed: 35251305
- Lee SH et al. Widespread intronic polyadenylation inactivates tumour suppressor genes in leukaemia. Nature 561:127-131 (2018). PubMed: 30150773